Hilliard Lyons Upgrades Meridian Bioscience (VIVO) to Long-Term Buy
More News related to VIVO
- Meridian Bioscience to Present at the William Blair and Company Small-Cap Growth Stock Conference
- Meridian Bioscience to Present at the 2008 UBS Global Life Science Conference
- Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes
- Meridian Bioscience (VIVO) Announces New Exclusive Canadian Distribution Agreement with Somagen Diagnostics
- Meridian Bioscience Announces New Exclusive Canadian Distribution Agreement with Somagen Diagnostics
More News related to Upgrades
- Fox-Pitt Starts First Commonwealth (FCF) and Susquehanna (SUSQ) at In Line
- Jefferies Starts Several Coal Names at Buy: JRCC, FCL, ICO
- Lazard Starts Broadcom (BRCM) at Hold
- Wedbush Morgan Initiates Coverage of Ascent Solar Technologies (ASTI) with a Hold
- Wedbush Morgan Initiates Coverage of Energy Conversion Devices (ENER) with a Buy
Hilliard Lyons upgrades Meridian Bioscience (Nasdaq: VIVO) from Neutral to Long-Term Buy.
Meridian Bioscience, Inc., a life science company, engages in the development, manufacture, sale, and distribution of diagnostic test kits primarily for respiratory, gastrointestinal, viral, and parasitic infectious diseases.
Related Categories
UpgradesStocks Mentioned
+0.15Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
